Video

VIDEO: CDK 4/6 inhibitors demonstrate “meaningful benefits” in metastatic, ER–positive breast cancer

In this video, Jane Meisel, MD, assistant professor in the department of hematology and medical oncology of Winship Cancer Institute at Emory University, reviews findings from two studies of CDK 4/6 inhibitors presented at the ASCO Annual Meeting.

The first trial, PALOMA-2, confirmed the data reported in the PALOMA-1 study. This phase 3 study compared palbociclib (Ibrance, Pfizer) plus letrozole vs. letrozole alone for women with metastatic, ER–positive breast cancer.

The second study, MONARCH1, examined the use of abemaciclib (LY2835219, Eli Lilly) as monotherapy. While the results of this investigation are early, they are still “exciting.”

Together, these investigations represent “important and exciting data for women who have ER-positive metastatic breast cancer,” according to Meisel.

“These CDK 4/6 inhibitors really can reverse endocrine resistance and lead to meaningful benefits … with very, very little toxicity,” she said.

In this video, Jane Meisel, MD, assistant professor in the department of hematology and medical oncology of Winship Cancer Institute at Emory University, reviews findings from two studies of CDK 4/6 inhibitors presented at the ASCO Annual Meeting.

The first trial, PALOMA-2, confirmed the data reported in the PALOMA-1 study. This phase 3 study compared palbociclib (Ibrance, Pfizer) plus letrozole vs. letrozole alone for women with metastatic, ER–positive breast cancer.

The second study, MONARCH1, examined the use of abemaciclib (LY2835219, Eli Lilly) as monotherapy. While the results of this investigation are early, they are still “exciting.”

Together, these investigations represent “important and exciting data for women who have ER-positive metastatic breast cancer,” according to Meisel.

“These CDK 4/6 inhibitors really can reverse endocrine resistance and lead to meaningful benefits … with very, very little toxicity,” she said.

    See more from ASCO Annual Meeting